A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01

BACKGROUND: Pediatric low-grade gliomas (PLGG) are the most frequent brain tumors in children. Up to 50% will be refractory to conventional chemotherapy. It is now known that the majority of PLGG have activation of the MAPK/ERK pathway. The same pathway is also activated in plexiform neurofibromas (...

Descripción completa

Detalles Bibliográficos
Autores principales: Perreault, Sébastien, Larouche, Valérie, Tabori, Uri, Hawkin, Cynthia, Lippé, Sarah, Ellezam, Benjamin, Décarie, Jean-Claude, Théoret, Yves, Métras, Marie-Élaine, Sultan, Serge, Cantin, Édith, Routhier, Marie-Ève, Caru, Maxime, Legault, Geneviève, Bouffet, Éric, Lafay-Cousin, Lucie, Hukin, Juliette, Erker, Craig, Jabado, Nada
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6935133/
https://www.ncbi.nlm.nih.gov/pubmed/31881853
http://dx.doi.org/10.1186/s12885-019-6442-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6935133/
https://www.ncbi.nlm.nih.gov/pubmed/31881853
http://dx.doi.org/10.1186/s12885-019-6442-2

Ejemplares similares